A proof-of-concept study on the genomic evolution of Sars-Cov-2 in molnupiravir-treated, paxlovid-treated and drug-naïve patients

Little is known about SARS-CoV-2 evolution under Molnupiravir and Paxlovid, the only antivirals approved for COVID-19 treatment. By investigating SARS-CoV-2 variability in 8 Molnupiravir-treated, 7 Paxlovid-treated and 5 drug-naïve individuals at 4 time-points (Days 0-2-5-7), a higher genetic distan...

Descripción completa

Detalles Bibliográficos
Autores principales: Alteri, Claudia, Fox, Valeria, Scutari, Rossana, Burastero, Giulia Jole, Volpi, Sara, Faltoni, Matteo, Fini, Vanessa, Granaglia, Annarita, Esperti, Sara, Gallerani, Altea, Costabile, Valentino, Fontana, Beatrice, Franceschini, Erica, Meschiari, Marianna, Campana, Andrea, Bernardi, Stefania, Villani, Alberto, Bernaschi, Paola, Russo, Cristina, Guaraldi, Giovanni, Mussini, Cristina, Perno, Carlo Federico
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9753865/
https://www.ncbi.nlm.nih.gov/pubmed/36522489
http://dx.doi.org/10.1038/s42003-022-04322-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9753865/
https://www.ncbi.nlm.nih.gov/pubmed/36522489
http://dx.doi.org/10.1038/s42003-022-04322-8

Ejemplares similares